|
|
Vaccine Detail
|
pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine |
| Vaccine Information |
- Vaccine Name: pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007137
- Type: DNA vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- IGFBP1
gene engineering:
- Description: This is for Ovarian Cancer (NCT01322802). A recombinant plasmid DNA vaccine containing mammalian expression vector, pUMVC3, encoding epitopes of human Insulin-Like Growth Factor-Binding Protein 2 (hIGFBP-2) with potential antineoplastic activity. Upon vaccination, pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine may produce IGFBP-2 that binds to cell surface, likely via integrin complexes. This results in the dephosphorylation of the focal adhesion-kinase (FAK) and of the p42/44 MAP-kinases, thereby inactivating them; both kinases are involved in cell growth regulation. Furthermore, IGFBP-2 promotes de-adhesion of the cells in a dose-dependent manner, hence impeding cell proliferation. The primary effect of IGFBPs appears to be modulation of IGF activity and control of IGF-mediated cell growth and metabolism (Johnson et al., 2007; NCIT_C95727).
|
| Host Response |
|
|
| References |
Johnson et al., 2007: Johnson LE, Frye TP, Chinnasamy N, Chinnasamy D, McNeel DG. Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells. Cancer immunology, immunotherapy : CII. 2007; 56(6); 885-895. [PubMed: 17102977].
NCIT_C95727: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C95727]
NCT01322802: [https://clinicaltrials.gov/show/NCT01322802]
|
|
